FIELD: immunology.
SUBSTANCE: present invention relates to immunology. What is presented is a cannibuted antibody for treating PD-1 mediated diseases. What is also considered is a pharmaceutical composition.
EFFECT: present invention can find further application in therapy of various diseases, particularly cancer and infections.
10 cl, 10 dwg, 5 ex, 14 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DOG ANTIBODIES WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2801209C2 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
| ANTIBODIES TO CANINE PD-1 | 2014 |
|
RU2761663C2 |
| CANINISED MURINE ANTIBODIES TO HUMAN PD-1 | 2014 |
|
RU2676158C1 |
| ANTI-CANINE CTLA-4 ANTIBODY | 2020 |
|
RU2818586C2 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| ANTIBODIES TO CANINE INTERLEUKIN-4 ALPHA RECEPTOR | 2016 |
|
RU2736732C2 |
| CANINIZED ANTI-HUMAN CTLA-4 ANTIBODIES | 2020 |
|
RU2822460C2 |
| ANTIBODIES AGAINST NERVE GROWTH FACTOR AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2012 |
|
RU2644235C2 |
